Cryoport Inc. has raised its full-year 2025 revenue guidance to a range of $170 million to $174 million, reflecting continued strong performance across its business segments. In the third quarter of 2025, the company reported a 15% year-over-year increase in revenue to $44.2 million. Notably, revenue from commercial cell and gene therapy services grew 36% year-over-year to $8.3 million, while Life Sciences Services revenue increased 16%, including a 21% rise in BioStorage/BioServices revenue. Life Sciences Products revenue also saw a 15% year-over-year increase. The company's updated outlook is based on sustained momentum and robust results throughout the year.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cryoport Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA15461) on November 04, 2025, and is solely responsible for the information contained therein.
Comments